#Australia #Melbourne #Phantom Neuro #Prosthetic Control #CYBORG study

Phantom Neuro's First-In-Human Clinical Study: A New Dawn for Prosthetic Technology

Phantom Neuro, an innovative company specializing in advanced neural interfaces, has made a significant leap in medical technology with the recent approval for its first-in-human clinical trial, named CYBORG, in Australia. This pioneering study aims to evaluate the groundbreaking Phantom X system, which facilitates intuitive control of prosthetics for those with limb loss.

The CYBORG study will assess the safety, efficacy, and overall usability of the Phantom X device, which is designed to enable users to operate prosthetic hands and robotic devices using natural muscle movements. This endeavor represents a pivotal moment for Phantom Neuro, as it marks the transition from preclinical validation to human application. CEO Connor Glass expressed the excitement and importance of this milestone, stating, "For the first time, we're moving from preclinical validation to human implantation."

A Closer Look at the Phantom X Control System

The Phantom X system employs a minimally invasive approach by utilizing a small, implantable sensor array positioned just beneath the skin on the residual limb of the user. This innovative technology interprets the neuromuscular signals generated by the muscle and translates them into precise movements of a robotic limb. Unlike traditional neural interface technologies that often involve invasive brain or nerve surgeries, the Phantom Neuro design allows for control without directly interfacing with the nervous system, significantly mitigating associated risks.

Participants in this clinical study will undergo a single-day outpatient surgical procedure, followed by a recovery period of approximately two weeks. Once healed, they will be fitted with a compatible Phantom X prosthetic and evaluated over a course of 20 weeks. This structured timeline ensures comprehensive data collection about the device’s functionality and user experience.

Strategic Location and Collaboration for Enhanced Results

Conducted in Melbourne, Australia, the study utilizes the effective framework of the nation’s clinical trial regulations to provide a streamlined experience for participants and researchers alike. Phantom Neuro chose Australia for its efficient pathways for early-stage clinical trials, which ultimately supports the intentions for future FDA approvals and pivotal trials in the United States.

Furthermore, the study is spearheaded by Dr. Michael Lo, a renowned plastic surgeon at Cabrini Health, alongside a dedicated team, including coordinating principal investigator Dr. Max Ortiz-Catalan and prosthetic experts. This collaborative effort underscores the commitment to advancing prosthetic technology and improving lived experiences for individuals dealing with limb loss.

What Lies Ahead for Phantom Neuro

With this clinical trial, Phantom Neuro aims not only to gather vital data regarding the Phantom X system but also to refine its technology based on practical insights garnered from real-world usage. Vinod Sharma, the Head of Clinical and Scientific Affairs at Phantom Neuro, emphasized the value of the upcoming study as a critical reference point for future enhancements.

Phantom Neuro launched its journey at the prestigious Johns Hopkins University School of Medicine and has garnered financial support from notable investors, including Ottobock and Blackrock Neurotech. As it moves forward with trials and eventual commercialization, the company is poised to bring transformative solutions to the field of prosthetics.

In essence, the approval for the CYBORG study is not merely a regulatory success; it reflects a broader commitment to merging cutting-edge technology with compassionate healthcare. Phantom Neuro is set to redefine the possibilities for users of prosthetic devices, allowing for a future where intuitive control and independence are within reach for many.

For more details on this innovative venture, please visit www.phantomneuro.com.